专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09534056B2 Engineered TAA antibody-TNFSF member ligand fusion molecules 有权
标题翻译：工程TAA抗体-TNFSF成员配体融合分子
公开(公告)号：US09534056B2
公开(公告)日：2017-01-03
申请号：US14124565
申请日：2012-06-06
申请人： Iqbal Grewal , Michael Gresser , Sanjay Khare , Rashid Syed
发明人： Iqbal Grewal , Michael Gresser , Sanjay Khare , Rashid Syed
IPC分类号： C07K19/00 , C07K14/525 , C07K16/28 , A61K38/19 , A61K38/21 , A61K39/395 , A61K45/06 , C07K14/475 , A61K38/00
CPC分类号： C07K16/2887 , A61K38/00 , A61K38/191 , A61K38/212 , A61K39/39558 , A61K45/06 , C07K14/525 , C07K2319/00
摘要： The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-α, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities.
摘要翻译：本发明的领域涉及基因工程融合分子，制备所述融合分子的方法及其在抗肿瘤免疫治疗中的用途。更具体地，本发明涉及包含能够靶向肿瘤细胞的抗体（Ab）的工程化融合分子，所述抗体（例如RITUXIN？）与一个或多个能诱导肿瘤细胞凋亡的生物部分融合，例如肿瘤坏死因子超级家族（TNFSF）成员配体如TNF-α，CD40L，CD95L（也称为“FasL / Apo-1L”）和TRAIL / Apo-2L。重要的是，本发明的工程改造的融合分子将生物部位的死亡诱导性质保持在最佳浓度和降低的全身毒性。

2. 发明申请

US20140105860A1 ENGINEERED ANTIBODY-TNFSF MEMBER LIGAND FUSION MOLECULES 有权
标题翻译：工程抗体 - TNFSF成员配体融合分子
公开(公告)号：US20140105860A1
公开(公告)日：2014-04-17
申请号：US14124565
申请日：2012-06-06
申请人： Iqbal Grewal , Michael Gresser , Sanjay Khare , Rashid Syed
发明人： Iqbal Grewal , Michael Gresser , Sanjay Khare , Rashid Syed
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395 , C07K14/525 , A61K38/19 , A61K38/21
CPC分类号： C07K16/2887 , A61K38/00 , A61K38/191 , A61K38/212 , A61K39/39558 , A61K45/06 , C07K14/525 , C07K2319/00
摘要： The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-α, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities, thus improving the therapeutic index of the engineered fusion molecules.
摘要翻译：本发明的领域涉及基因工程融合分子，制备所述融合分子的方法及其在抗肿瘤免疫治疗中的用途。更具体地，本发明涉及包含能够靶向肿瘤细胞的抗体（Ab）的工程化融合分子，所述抗体（例如RITUXIN？）与一个或多个能诱导肿瘤细胞凋亡的生物部分融合，例如肿瘤坏死因子超级家族（TNFSF）成员配体如TNF-α，CD40L，CD95L（也称为“FasL / Apo-1L”）和TRAIL / Apo-2L。重要的是，本发明的工程化融合分子将生物部分的死亡诱导性质保持在最佳浓度并具有降低的全身毒性，从而改善了工程化融合分子的治疗指数。

3. 发明授权

US06904369B1 Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor 失效
标题翻译：通过实现干细胞因子受体的二聚化来刺激血细胞增殖的共轭配体
公开(公告)号：US06904369B1
公开(公告)日：2005-06-07
申请号：US09609027
申请日：2000-06-29
申请人： Wayne A. Hendrickson , Xuliang Jiang , Keith E. Langley , Rashid Syed , Yueh-Rong Ann Hsu
发明人： Wayne A. Hendrickson , Xuliang Jiang , Keith E. Langley , Rashid Syed , Yueh-Rong Ann Hsu
IPC分类号： A61K38/00 , C07H21/04 , C07K14/11 , G01N33/48 , C07K1/00 , G01N33/50
CPC分类号： C07K14/005 , A61K38/00 , C07H21/04 , C07K1/1077 , C12N2760/16022 , G06F19/16
摘要： This invention provides a computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing a SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF molecule for a desired characteristic. This invention also provides SCF analogs and SCF ligand analogs prepared according to the above-described method. Compositions comprising SCF analogs or SCF ligand analogs prepared according to the above-described method effective to treat a subject and a pharmaceutically acceptable carrier are provided, as are methods of treating a subject comprising administration of pharmaceutical compositions comprising the prepared SCF analogs and SCF ligand analogs prepared by the described methods. This invention also provides methods for designing compounds capable of binding to the SCF receptor site and compounds designed by the above-described methods.
摘要翻译：本发明提供了一种用于制备干细胞因子（SCF）类似物的基于计算机的方法，包括以下步骤：（a）使用其晶体结构提供SCF分子的三维结构的计算机表达; （b）选自步骤（a）的计算机表达，SCF分子上的至少一个位点用于改变; （c）制备在所述至少一个所选位点具有改变的SCF分子; 和（d）任选地，测试SCF分子的期望特性。本发明还提供了根据上述方法制备的SCF类似物和SCF配体类似物。提供了包含根据有效治疗受试者和药学上可接受的载体的上述方法制备的SCF类似物或SCF配体类似物的组合物，治疗受试者的方法包括施用包含制备的SCF类似物和SCF配体类似物的药物组合物通过描述的方法准备。本发明还提供了设计能够结合SCF受体位点的化合物和通过上述方法设计的化合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式